课题基金 / 基金详情

Pneumedoreductive Surfacant - New Therapy for Emphysema

Pneumedoreductive Surfacant - New Therapy for Emphysema
气减表面活性剂——肺气肿的新疗法
批准号:
6832418
负责人:
EDWARD P INGENITO
金额:
$9.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-20 至 2005-03-31

项目摘要

项目成果

EDWARD P INGENITO的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):本阶段I SBIR申请由Bistech,Inc.提交。的Woburn,MA。它将测试使用一种新的吸入药剂,减少肺表面活性剂(PRS),以治疗肺气肿,一个渐进的和致残的疾病,影响世界各地数百万人的可行性。现有的用于肺气肿的医学疗法,如支气管扩张剂和抗炎药,益处有限,因为它们没有解决这种疾病的基本生理缺陷:由肺的胶原蛋白和弹性蛋白纤维的破坏引起的弹性回缩的损失。两个因素决定肺弹性回缩:1)组织纤维网络的拉伸和2)由肺泡气液界面处的表面膜产生的表面张力。从理论上讲,肺气肿的弹性回缩可以通过修复组织纤维网络或增加表面张力来恢复。虽然药物治疗不能轻易实现前者,但它们可能能够实现后者。Bistech已经开发出减少肺功能的表面活性剂的原型制剂。在初步的体外测试和短期的体内测试中,这些制剂似乎有效且安全地增加了回缩。这里提出的研究将扩展这些初步观察结果,并检查是否可以开发用于临床测试的PRS。本提案的具体目的是在准确代表人类疾病的肺气肿实验模型中评价PRS给药的短期和长期生理学和生物学反应。这些研究旨在提供有关PRS对体内肺功能影响的详细信息,并确定长期暴露于PRS的任何潜在毒性作用。如果第一阶段证明成功,将提交第二阶段申请,以完成临床前动物试验和产品配方,启动药理学-毒理学研究,制定生产计划,并开始计划在人类患者中进行第一阶段临床试验。
英文摘要
DESCRIPTION (provided by applicant): This Phase I SBIR application is presented by Bistech, Inc. of Woburn, MA. It will test the feasibility of using a new inhaled pharmaceutical agent, pneumoreductive surfactant (PRS), to treat pulmonary emphysema, a progressive and disabling disease that affects millions of individuals throughout the world. Existing medical therapies for emphysema, such as bronchodilators and anti-inflammatory drugs, are of limited benefit since they do not address the fundamental physiological defect in this disease: loss of elastic recoil caused by destruction of the collagen and elastin fibers of the lung. Two factors determine lung elastic recoil: 1) stretching of the tissue fiber network and 2) surface tension generated by the surface film at the alveolar air-liquid interface. In, theory, elastic recoil could be restored in emphysema either by repairing the tissue fiber network or by increasing surface tension. While medical therapies cannot readily accomplish the former, they may be able to accomplish the latter. Prototype formulations of pneumoreductive surfactant have been developed by Bistech. In preliminary in vitro testing and short term in vivo testing, these formulations appear to increase recoil effectively and safely. The studies proposed here will extend these preliminary observations, and examine whether PRS can be developed for clinical testing. The specific aim of this proposal is to evaluate short and long term physiological and biological responses to PRS administration in an experimental model of emphysema that accurately represents the disease as it presents in humans. The studies are designed to provide detailed information about the effects of PRS on lung function in vivo, and to identify any potential toxic effects of prolonged PRS exposure. If Phase I proves successful, a Phase II application will be filed to complete preclinical animal testing and product formulation, initiate pharmacology-toxicology studies, develop a manufacturing plan, and begin the planning of a Phase 1 clinical trial in human patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pneumografting - a novel cell-based therapy for emphysema
  • 批准号:
    7677276
  • 项目类别:
  • 资助金额:
    $59.17万
  • 财政年份:
    2007
  • 负责人:
    EDWARD P INGENITO
  • 依托单位:
Pneumografting - a novel cell-based therapy for emphysema
  • 批准号:
    7879276
  • 项目类别:
  • 资助金额:
    $58.12万
  • 财政年份:
    2007
  • 负责人:
    EDWARD P INGENITO
  • 依托单位:
Pneumografting - a novel cell-based therapy for emphysema
  • 批准号:
    7334362
  • 项目类别:
  • 资助金额:
    $58.37万
  • 财政年份:
    2007
  • 负责人:
    EDWARD P INGENITO
  • 依托单位:
Pneumoreductive Surfactant Therapy for Emphysema
  • 批准号:
    7232000
  • 项目类别:
  • 资助金额:
    $7.08万
  • 财政年份:
    2004
  • 负责人:
    EDWARD P INGENITO
  • 依托单位: